Numerion Labs Overview
Pro stress-test →Numerion Labs specializes in AI-based drug discovery services, developing small-molecule drug candidates using atomnet technology, which employs deep learning for structure-based drug design. The company rebranded from Atomwise in October 2025, with a strategic focus on ultra-fast virtual screening (APEX) and immune/inflammatory disease programs.
Strategic Profile
Pro stress-test →The company collaborates with over 250 partners, including pharmaceutical and biotechnology companies, to address various disease targets. Numerion Labs developed APEX to address the inability to comprehensively search chemical space at scale, pairing deep learning surrogates with GPU-accelerated enumeration to virtually evaluate billions of potential starting points in seconds.
Competitive Landscape
Pro stress-test →BenevolentAI concentrates on upstream target and indication discovery using knowledge-graph-driven biology, while Insilico spans an end-to-end generative AI pipeline with autonomous lab and clinical assets, whereas Numerion specializes in structure-based virtual screening for small-molecule hits. Other noted competitors include X-37, Exscientia, Inovio Pharmaceuticals, Verge Analytics, and Enterprise Therapeutics.
Industry Context
Numerion Labs operates in AI-driven small molecule drug discovery.
Key facts
Founded: 2012 · Headquarters: San Francisco, US · Employees: 67 · Revenue: N/A · Market cap: N/A